Core Viewpoint - The "2026 Maritime Light" academic conference on optometry and visual science highlighted Huaxia Eye Hospital's achievements in refractive surgery, showcasing its innovative practices and clinical quality, which earned multiple prestigious awards [1][4][24]. Group 1: Awards and Recognition - Huaxia Eye Hospital received the "High-Quality Development Contribution Award" for performing over 7,000 new SMILE pro surgeries, reflecting its commitment to standardized, safe, and high-quality surgical practices [4]. - The Xiamen University Affiliated Xiamen Eye Center completed over 3,500 surgeries, while Chengdu Aidi Eye Hospital and Zhengzhou Huaxia Vision Eye Hospital completed over 1,500 and 1,300 surgeries respectively, earning them the "High-Quality Development Contribution Award" for exceeding 1,000 cases [8]. - Huaxia Eye Hospital was recognized with the "Non-Public Medical EVO ICL Project Innovation Breakthrough Award" for its extensive experience and advancements in ICL technology since 2010 [15]. Group 2: Technological Advancements - The hospital introduced the new EVO+ ICL (V5) technology, establishing a nationwide clinical application network and enhancing its leadership in refractive surgery [12]. - The launch of the "Large Optical Zone Intraocular Lens ICL (V5)" technology was a significant milestone, showcasing Huaxia Eye Hospital's expertise and experience in the field [11]. Group 3: Academic Contributions - Huaxia experts actively participated in various academic sessions, demonstrating their influence and technical capabilities in the field of refractive surgery [23]. - The hospital's commitment to academic exchange was evident through its involvement in specialized discussions and practical training sessions during the conference [21][23]. Group 4: Strategic Development - Huaxia Eye Hospital's success is attributed to over 20 years of dedication in the refractive surgery field, focusing on the integration of technology, talent, platform, and service [24]. - The hospital aims to enhance its dual strategy of "corneal laser surgery" and "intraocular lens surgery," accelerating the clinical research of EVO+ ICL (V5) and expanding the application of advanced technologies like new SMILE pro and all-light shaping [24].